Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD

This Phase 2a, double-blind, parallel, 6-arm study aims to evaluate the efficacy and safety of frexalimab, brivekimig, and rilzabrutinib in patients aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The study will enroll 84 participants and will last up to 76 weeks, with a treatment duration of 24 weeks. Participants will attend up to 18 visits. The primary endpoint is the percent reduction in urine protein to creatinine ratio (UPCR), which serves as a measure of proteinuria reduction. Secondary endpoints and detailed safety profiles will be assessed, although specific statistics such as hazard ratios, odds ratios, or confidence intervals are not yet available. The trial is sponsored by Sanofi and is currently recruiting, with an estimated primary completion date of December 23, 2026. The study's outcomes could potentially inform treatment strategies for FSGS and MCD, focusing on reducing proteinuria as a key therapeutic target.

Imagine living with a kidney disease that makes you feel constantly unwell and limits your daily life. For many, primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) can feel like an uphill battle, as current treatments don’t work for everyone. This study is exploring three new drugs—frexalimab, brivekimig, and rilzabrutinib—to see if they can effectively reduce protein in urine, a key indicator of kidney health. Over 76 weeks, participants will receive one of these treatments or a placebo, with the hope of finding a better way to manage their symptoms. If these drugs prove effective, they could lead to fewer people experiencing the debilitating effects of nephrotic syndrome, which is often tied to these kidney diseases. However, it's important to remember that these treatments are still in the testing phase, and we need to wait for the results to understand their true impact. The journey to better kidney health continues, and this research offers a glimmer of hope for those affected.